Simponi Aria (golimumab) for Intravenous Use
Customize your policy alerts
Sign up for Bluecross Idaho Policy MP 5.01.670 alerts
Get alerted when Policy MP 5.01.670 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical-benefit coverage and prior-authorization criteria for intravenous golimumab (Simponi Aria) for specified inflammatory indications; it affects providers administering IV golimumab and members whose benefit plans follow Blue Cross of Idaho policies.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.